君实生物(01877.HK)认购Anwita优先股合作研发治疗药
君实生物(01877.HK)公布,认购Anwita 299万股优先股,占其发行在外股份20%,现金代价1,000万美元。Anwita专注於创新蛋白质工程,以生成用於免疫肿瘤学(IO)的同类最优细胞因子。
同时,双方订立许可协议,於大中华区开发及商业化Anwita的创新IL-21融合蛋白AWT008。完成AWT008技术转让後,公司须支付现金200万美元。此外,若AWT008符合提交IND的要求,公司可批准继续提交IND并进行随後的临床试验以就其商业销售获得监管许可。因此,Anwita将有权就AWT008计划的开发里程碑中收取合共最高6,450万美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.